Loading clinical trials...
Loading clinical trials...
A Phase 2, Randomized, Double-Blind, Multicenter Study of Safety, Tolerability, and Efficacy of Debio 1450 vs Vancomycin (IV)/Linezolid (Oral) in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Due to Staphylococcus Sensitive or Resistant to Methicillin
Conditions
Interventions
Debio 1450 IV
Debio 1450 Oral
+4 more
Locations
22
United States
Dream Team Clinical Research, LLC
Anaheim, California, United States
Physician Alliance Research Center
Anaheim, California, United States
Southbay Pharma Research
Buena Park, California, United States
eStudySite - Chula Vista
Chula Vista, California, United States
eStudySite - La Mesa
La Mesa, California, United States
Long Beach Clinical Trials LLC
Long Beach, California, United States
Start Date
May 1, 2015
Primary Completion Date
August 1, 2016
Completion Date
September 1, 2016
Last Updated
November 13, 2019
NCT04263792
NCT06135350
NCT06322277
NCT06319235
NCT05824988
NCT05914467
Lead Sponsor
Debiopharm International SA
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions